issued last november by the national academies of science, 17 people, chaired by a man called norm augustine who was the former ceo of lockheed martin and their two chief recommendations to lower drug prices were that medicare should be able to negotiate directly for drug prices and reform. those two things from the national academy of sciences completely missing so far from any of the white house proposals. >> mary is an island heights new jersey. good morning. >> thehe morning. i want to bring attention to the unanimous approval of the 2012 fda safety and invasion act which gave fda the right to charge fees for generic drug manufacturers.s these fees are unfair because if you make a thousand generic drugs this year you pay $248,000. generic drugne your fee is $248,000. 65 generic drug manufacturers have gone out of business because of the structure. >> .familiar with the generic fee structure for fda user fees.. i canis say this, the way we expresss competition to drive down prices underis the legal framework we host: to tammy in vienna, virginia. good morning. caller: hi. understanding is

issued last november by the national academies of sciences, 17 august people, it was chaired by norm augustine, former c.e.o. of lockheed martin and two cheap recommendations to lower drug prices in this country were medicare should be able to negotiate directly for drug prices and we need patent reform. those things from national academy of sciences, those two things completely missing from the white house proposals. host: barry in island heights, new jersey. good morning. caller: good morning. i wanted to bring attention to the unanimous approval of the 2012 fda safety and innovation act. it gives the fda the right to charge fees for generic drug manufacturers. these fees are unfair, because drugs make 1000 generic this year and pay $240,000. if you make one generic drug, your fee is $240,000. 65 generic drug manufacturers have gone out of business because of this structure. with: i am not familiar the generic fee structure for fda user fees. competitionxpress to drive down prices under the legal framework we have in this country is we allow generics to come to market after the brand has a t

norm augustine told me once, stop ranting about the industrial base, they are simply mirroring the system that you have and it's human nature. it's true. we have to change that and we are looking forward to opening the doors for this relationship concept, it's out there and i know it will come. just to strengthen them because i don't have the amount of funds that i need for the requirements that are being heaped on me. i need to increase my capabilities and every single aspect were i do business. the only way i can do that is by working in partnership with the industrial base and in that lin line, that sends the trickle down to michael who will make the investments appropriate because capital is the universal lubricant for my business, in order for my suppliers and my supply chain to function correctly. >> your kind of caught in the middle because you've got michael who is demanding those quarterly earnings. you have a client who wants the best technology for the future so how are you thinking about it. >> there's the dilemma. we are public companies subject to competitive pressures, we h

report that a fine was issued last november by the sciences, ademies of chairedt people, it was by norm augustineformer c.e.o. lockheed martin and two cheap recommendations to lower drug country were medicare should be able to negotiate directly for drug we need patent reform. things from national academy of sciences, those two things completely missing from the white house proposals. barry in island heights, new jersey. good morning. morning.ood i wanted to bring attention to he unanimous approval of the 2012 f.d.a. safety and innovation act giving f.d.a. the right to charge fees for generic manufacturers. ifse fees are unfair because you make 1000 generic drugs this $248,000.pay f you make one generic drug, your fee is $248,000. manufacturers have gone out of business because of the fee structure. intimately not familiar with the generic fee f.d.a. user fees. i can say this, the way we drive competition to down prices under the legal framework we have in this ountry is that we allow generics to come to market after the brand has a time of exclusivity. first generic generally reduces the price t